10:04 AM EST - ProMIS Neurosciences, Inc. : Announced that its lead product candidate for Alzheimer's disease, PMN310, showed the desired binding profile of selectively targeting amyloid beta oligomers in a preclinical study directly comparing PMN310 to other amyloid beta-directed antibodies for Alzheimer's disease. ProMIS Neurosciences, Inc.
shares T.PMN are trading unchanged at $0.24.
